TCR T-cell therapy (Yinkang Biopharma)

N/A

Report date: 2025/03/20 09:41:30

Base Information

Drug NameTCR T-cell therapy (Yinkang Biopharma)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Recombinant proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionHuman leukocyte antigen modulators

TargetsHuman leukocyte antigen

Therapy Area/IndicationsHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesYinkang Biopharma Inc.

China Registration ClassN/A

Develop Information

Active CompaniesYinkang Biopharma Inc.

Inactive CompaniesN/A

Active IndicationsHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A